Literature DB >> 17630818

CNS aspergillosis: recognition, diagnosis and management.

Markus Ruhnke1, Grzegorz Kofla, Kirsten Otto, Stefan Schwartz.   

Abstract

Early diagnosis of CNS aspergillosis requires a high degree of clinical suspicion, because there are no typical clinical symptoms or CSF findings. Clinical features are usually dramatic and tend to progress rapidly. Changes in mental status, hemiparesis and seizures are most common, but other nonspecific neurological features may occur and should always be an indication for neuroradiological examination in high-risk patients, in order to allow early initiation of antifungal therapy. Low density lesions with little or no mass effect and minimal or no contrast enhancement on CT scans that are usually more numerous on MRI and show intermediate signal intensity within high-signal areas on T2-weighted images, may suggest CNS aspergillosis. Cerebral lesions in CNS aspergillosis are often located not only in the cerebral hemispheres but also in the basal ganglia, thalami, corpus callosum and perforator artery territories. There is frequently a lack of contrast enhancement or perifocal oedema, due to the immunosuppressed status of the patient. A definite diagnosis requires brain tissue for histopathological analysis. However, neurosurgery is often not feasible, so that any of the neuroradiological findings mentioned above should raise the suspicion of CNS aspergillosis in immunocompromised patients and lead to early initiation of antifungal therapy. In the past, amphotericin B-based therapy was the treatment of choice for CNS aspergillosis, but this treatment produced negligible effects. Recently, voriconazole has been reported to be more effective than amphotericin B in the treatment of invasive aspergillosis. Response rates of about 35% have been achieved with voriconazole in patients with CNS aspergillosis. Combination therapy with antifungal agents, such as voriconazole plus caspofungin or liposomal amphotericin B, is being investigated in vitro and in animal models, and optimistic results have been observed. A combined medical and neurosurgical treatment should be considered in all patients with this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17630818     DOI: 10.2165/00023210-200721080-00004

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  100 in total

Review 1.  Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis.

Authors:  Monique A S H Mennink-Kersten; J Peter Donnelly; Paul E Verweij
Journal:  Lancet Infect Dis       Date:  2004-06       Impact factor: 25.071

2.  Successful treatment of brain aspergillosis with voriconazole.

Authors:  P Tattevin; F Bruneel; F Lellouche; T de Broucker; S Chevret; M Wolff; B Régnier
Journal:  Clin Microbiol Infect       Date:  2004-10       Impact factor: 8.067

3.  Central nervous system aspergillosis: a 20-year retrospective series.

Authors:  B K Kleinschmidt-DeMasters
Journal:  Hum Pathol       Date:  2002-01       Impact factor: 3.466

Review 4.  Intracavitary administration of amphotericin B in the treatment of cerebral aspergillosis in a non immune-compromised patient: case report and review of the literature.

Authors:  E A Elgamal; W R Murshid
Journal:  Br J Neurosurg       Date:  2000-04       Impact factor: 1.596

Review 5.  Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome.

Authors:  D H Mitchell; T C Sorrell; A M Allworth; C H Heath; A R McGregor; K Papanaoum; M J Richards; T Gottlieb
Journal:  Clin Infect Dis       Date:  1995-03       Impact factor: 9.079

Review 6.  Micafungin.

Authors:  Blair Jarvis; David P Figgitt; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Brain parenchymal infection in bone marrow transplantation patients: CT and MR findings.

Authors:  W T Yuh; H D Nguyen; F Gao; E T Tali; D J Fisher; N A Mayr; D P Mueller; Y Sato; M E Trigg; R Gingrich
Journal:  AJR Am J Roentgenol       Date:  1994-02       Impact factor: 3.959

Review 8.  Stereotactic drainage of Aspergillus brain abscess with long-term survival: case report and review.

Authors:  M L Goodman; R J Coffey
Journal:  Neurosurgery       Date:  1989-01       Impact factor: 4.654

9.  Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

Authors:  T J Walsh; J W Hiemenz; N L Seibel; J R Perfect; G Horwith; L Lee; J L Silber; M J DiNubile; A Reboli; E Bow; J Lister; E J Anaissie
Journal:  Clin Infect Dis       Date:  1998-06       Impact factor: 9.079

10.  Aspergillosis of the central nervous system: clinicopathological analysis of 17 patients.

Authors:  T J Walsh; D B Hier; L R Caplan
Journal:  Ann Neurol       Date:  1985-11       Impact factor: 10.422

View more
  15 in total

Review 1.  [Infections of the central nervous system in the immuno-compromised].

Authors:  E Schmutzhard; B Pfausler
Journal:  Nervenarzt       Date:  2008-09       Impact factor: 1.214

Review 2.  Role of microglia in fungal infections of the central nervous system.

Authors:  George W Koutsouras; Raddy L Ramos; Luis R Martinez
Journal:  Virulence       Date:  2016-11-18       Impact factor: 5.882

3.  Cerebral aspergillosis with multiple enhancing nodules in the right cerebral hemisphere in the immune-competent patient.

Authors:  Gwang-Jun Lee; Tae-Young Jung; Seong-Min Choi; Min-Young Jung
Journal:  J Korean Neurosurg Soc       Date:  2013-05-31

Review 4.  Fungal infections in pediatric neurosurgery.

Authors:  Adrian Caceres; Maria Luisa Avila; Marco Luis Herrera
Journal:  Childs Nerv Syst       Date:  2018-08-18       Impact factor: 1.475

5.  Intracranial Aspergillosis in an Immunocompetent Young Woman.

Authors:  Prasan Kumar Panda; Sunil Kumar Mavidi; Naveet Wig; Ajay Garg; Aasma Nalwa; M C Sharma
Journal:  Mycopathologia       Date:  2017-01-04       Impact factor: 2.574

Review 6.  [Molecular biological identification of fungal pathogens in FFPE tissue from cases of cephalic mycosis].

Authors:  A Bernhardt; L de Boni; H A Kretzschmar; K Tintelnot
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

Review 7.  [Aspergillus in airway material : Ignore or treat?]

Authors:  H J F Salzer; C Lange; M Hönigl
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

Review 8.  Infections in the immunocompromised child.

Authors:  Llewellyn C Padayachy; A Graham Fieggen
Journal:  Childs Nerv Syst       Date:  2018-07-11       Impact factor: 1.475

9.  Invasive fungal infection of the central nervous system in a patient with acute myeloid leukaemia.

Authors:  Anna Janik-Moszant; Aleksander Matyl; Iwona Rurańska; Agnieszka Machowska-Majchrzak; Ewa Kluczewska; Tomasz Szczepański
Journal:  Pol J Radiol       Date:  2012-01

10.  Complement Attack against Aspergillus and Corresponding Evasion Mechanisms.

Authors:  Cornelia Speth; Günter Rambach
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.